Male Pattern Hair Loss

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK
PROPECIA® (finasteride) 1mg This site is intended only for healthcare professionals of the United States,
its territories, and Puerto Rico. Non-US residents click here. 		 PROPECIA Packaging
Home Prescribing Information Patient Product Information Patient Website
Product Data and Highlights
Highlights of Clinical Studies
Clinical Hair Count Results
Photographic Assessment
Patient Self-Assessment
Investigator Assessment
Hair Weight Results
Selected Safety Information
How PROPECIA Works
Study Design
Prescribing PROPECIA
Resources
5-Year Data
See the results of the longest reported controlled clinical study of male pattern hair loss.
View study results.
 
Clinical Hair Count Results—Difference Over 5 Years
 
 Difference over 5 years  When to start treatment

In the longest reported controlled clinical study of male pattern hair loss patients ever conducted ...

Most (65%) men treated with PROPECIA® (finasteride) at Year 5 had increased hair count, while all men in the placebo group experienced hair loss1
Difference in Hair Count Up to 5 Years
Pooled data from 2 vertex studies (mean baseline hair count=876).
P<0.001 PROPECIA vs baseline at each time point.
P<0.001 placebo vs baseline at each time point.
The difference in hair count mean change from baseline of 277 hairs was seen between men taking PROPECIA vs placebo at 5 years.
* Changes in hair count were measured within a 1-inch diameter circle at the anterior leading edge of the thinning vertex area.
Hair loss is a progressive condition—those patients left untreated may continue to lose hair.
The maximum improvement in hair count with PROPECIA compared to baseline was achieved during the first 2 years.
PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.
PROPECIA is not indicated in women or children.
If PROPECIA has not maintained hair count or regrown visible hair within 12 months, further treatment is unlikely to be of benefit. Withdrawal of treatment leads to reversal of effect within 12 months.

 Difference over 5 years  When to start treatment

 

    PROPECIA is a registered trademark of Merck & Co., Inc.
20753248(2)-12/07–PRP